We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ashland to Hike Price of Composites Products in North America
Read MoreHide Full Article
Ashland Global Holdings Inc. (ASH - Free Report) is set to hike the price of composites products portfolio in North America, including the United States, Mexico and Canada. The hiked rates will be effective from Apr 22, 2019 or as contracts permit.
Per the company, ortho-phthalic resins prices will rise by 6 cents per pound and all other unsaturated polyester resins will rise by 4 cents per pound. Prices of vinyl ester, fire retardant & specialty resins will rise by 5 cents per pound. Chlorendic based resins prices will rise by 9 cents per pound and all gelcoats & pigments prices will rise by 5 cents per pound.
Moreover, Ashland stated that the hike is mainly driven by persistent increase in cost of key raw materials, freight and tariffs (particularly for Chlorendic based resins). The company’s latest price hike is intended to provide customer services with the highest quality and performance.
Shares of Ashland have gained 14.1% in a year’s time compared with the industry’s 7.5% rise.
Ashland expects adjusted earnings per share (EPS) in the range of $3.10-$3.40 for fiscal 2019.
Adjusted EBITDA in the Specialty Ingredients unit is projected in the range $610-$635 million. In the Intermediates & Solvents business, adjusted EBITDA is projected in the band of $20-$30 million. Free cash flow for fiscal 2019 is expected around $175 million.
For second-quarter fiscal 2019, the company projects adjusted EPS from continuing operations in the range of 80-90 cents per share, assuming that effective tax rate is 15%.
Kirkland has an expected earnings growth rate of 8.8% for 2019. The company’s shares have surged 83.1% in the past year.
Rio Tinto has an expected earnings growth rate of 20.1% for the current year. The company’s shares have gained 17.4% in a year’s time.
Materion has an expected earnings growth rate of 12.6% for 2019. Its shares have gained 11.4% in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Ashland to Hike Price of Composites Products in North America
Ashland Global Holdings Inc. (ASH - Free Report) is set to hike the price of composites products portfolio in North America, including the United States, Mexico and Canada. The hiked rates will be effective from Apr 22, 2019 or as contracts permit.
Per the company, ortho-phthalic resins prices will rise by 6 cents per pound and all other unsaturated polyester resins will rise by 4 cents per pound. Prices of vinyl ester, fire retardant & specialty resins will rise by 5 cents per pound. Chlorendic based resins prices will rise by 9 cents per pound and all gelcoats & pigments prices will rise by 5 cents per pound.
Moreover, Ashland stated that the hike is mainly driven by persistent increase in cost of key raw materials, freight and tariffs (particularly for Chlorendic based resins). The company’s latest price hike is intended to provide customer services with the highest quality and performance.
Shares of Ashland have gained 14.1% in a year’s time compared with the industry’s 7.5% rise.
Ashland expects adjusted earnings per share (EPS) in the range of $3.10-$3.40 for fiscal 2019.
Adjusted EBITDA in the Specialty Ingredients unit is projected in the range $610-$635 million. In the Intermediates & Solvents business, adjusted EBITDA is projected in the band of $20-$30 million. Free cash flow for fiscal 2019 is expected around $175 million.
For second-quarter fiscal 2019, the company projects adjusted EPS from continuing operations in the range of 80-90 cents per share, assuming that effective tax rate is 15%.
Zacks Rank & Key Picks
Ashland currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Kirkland Lake Gold Ltd. , Rio Tinto plc (RIO - Free Report) and Materion Corporation (MTRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kirkland has an expected earnings growth rate of 8.8% for 2019. The company’s shares have surged 83.1% in the past year.
Rio Tinto has an expected earnings growth rate of 20.1% for the current year. The company’s shares have gained 17.4% in a year’s time.
Materion has an expected earnings growth rate of 12.6% for 2019. Its shares have gained 11.4% in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>